Faron Pharmaceuticals Oy is a Finland-based biopharmaceutical company engaged in the biotechnology and medical research industry. The Company develops late stage clinical drugs focusing on acute organ traumas, cancer immunotherapy and vascular damage. Its product pipeline includes Traumakine (FP-1201-lyo), an Acute Respiratory Distress Syndrome (ARDS) treatment that is in phase Three development; and Clevegen (FP-1304), an anti-Clever-1 immunotheraphy tumor targeting candidate that is in pre-clinical stage development.